Abstract A new iron-based T 1 contrast agent consisting of a complex of iron ions coordinated to phosphate and amine ligands (Fe (phos) in short) has been characterized by spectroscopic and magnetic measurements. NMR relaxation studies showed r 1 values to be dependent on the phosphate salt concentration, K 2 HPO 4 , present in the medium. r 1 reaches a maximum value of 2.5 mM −1 s −1 for measurements carried out at 7 T and 298 K. 31 P MRS, Mössbauer spectroscopy and magnetic measurements of Fe (phos) solutions suggest paramagnetic Fe 3+ ions present in the studied iron-phosphate complex. In vitro and in vivo toxicity experiments with C6 cells and CD1 mice, respectively, demonstrated lack of toxicity for Fe (phos) at the highest dose tested in the MRI experiments (12 mM iron for C6 cells and 0.32 mmol iron/kg for mice). Finally, T 1 weighted images of brain tumours in mice have shown positive contrast
Introduction
Magnetic resonance imaging (MRI) is one of the most powerful techniques in clinical diagnostic medicine and in non-invasive biomedical research and has fostered the development of agents designed to enhance tissue differentiation in vivo. The effect of these agents, mainly complexes of Gd 3+ , Fe 3+ , and Mn 2+ , is known to improve contrast in MR-based images (1, 2) . MRI contrast agents (CA) act by accelerating the relaxation process of water protons in tissues by selectively decreasing both the longitudinal relaxation time, T 1 , and the transversal relaxation time, T 2 . Gd 3+ complexes have received most attention as contrast agents for MRI applications due to their large magnetic moment and a suitable long electronic relaxation time. However, there is no natural human biochemistry for Gd 3+ that can be exploited when designing its contrast agents derivates (3) (4) (5) (6) . On the other hand, agents based on Mn 2+ , Fe 3+ , and Cu
2+
ions are attractive alternatives (7-9) because these metals are already present in tissues and there is extensive information available about their human biochemistry, including transport, storage, compartmentalization and excretion mechanisms. Many of the iron-based contrast agents consist of superparamagnetic particles of colloidal iron oxides that cause T 2 -enhancement (10, 11) . A second type of iron-based contrast agents are iron(III) mononuclear complexes. In this case the ligands provide coordinative saturation to the iron, avoiding the occurrence of Lewis acid-catalyzed hydrolysis reactions and redox processes (12) , toxic to the body and which are potentially facilitated by free Fe 3+ ions. Furthermore, Fe 3+ ions must be chelated to avoid precipitation caused losses near pH ∼7.
The complex [(tacn) 6 Fe 8 (µ 3 -O) 2 (µ 2 -OH) 12 ]Br 8 · 9H 2 O, where tacn = 1,4,6-triazacyclononane, and hereafter referred to as Fe 8 , was chosen by us in order to study its potential as contrast agent (13) . Due to the size of Fe 8 molecules, the distribution and residence time in the tissues should be different and produce complementary information to that given by Gd-based chelates and iron oxide nanoparticles. A major shortcoming of clinical and experimental MR contrast agents is that they are limited to reporting anatomic detail only. Nevertheless, significant progress has been made on the design and preparation of MR agents that are brighter, selectively targeted and have a longer residence time in vivo (14, 15) .
In this work, we present the unexpected relaxometric properties of the solutions obtained by adding a known amount of the Fe 8 molecule to phosphate salt solutions at different concentrations of K 2 HPO 4 , and hereafter referred as Fe (phos) . Spectroscopic and magnetic studies of the Fe (phos) solutions were also carried out. The results have shown the instability of the Fe 8 precursor in phosphate solutions and the formation of a new timestable species, Fe (phos) , rapidly established among the Fe 3+ ions and amine ligands present in the Fe 8 cluster and phosphate ions. Therefore we hypothesized that the new contrast agent described in this work could be potentially useful to report on hyperphosphatemic regions inside a living organism. Before embarking in such a study, in vivo effect and tolerance need to be assayed. For this, toxicity studies of Fe (phos) solutions using C6 glioma cells were carried out. Furthermore, preliminary in vivo studies were also performed with mice to evaluate both toxicity, with control animals, and T 1 contrast enhancement for stereotactically induced brain tumours.
Experimental section
Reagents were purchased from Sigma Aldrich (Spain) and used as received without further purification. The synthesis of Fe 8 was performed as described by Wieghardt et al. (16) . A special batch enriched with 57 Fe isotope was prepared to be used for the Mössbauer characterization.
NMR relaxation studies 1 H measurements were performed on a Bruker Avance 300 spectrometer operating at a magnetic field of 7.0 T at 298 K. Inversion-recovery (180
n -acquire) pulse sequences were used to measure T 1 and T 2 , respectively. Five millimeter-diameter NMR tubes, each containing deuterated water (used for locking purposes) and a capillary tub insert filled with the iron aqueous solutions, were used essentially as in (13) . Relaxation time constants were obtained by fitting the proper equation to the peak area data using a least-squares algorithm as implemented in the processing Bruker software. Correlation coefficients greater than 0.9 were obtained in all cases.
T 1 relaxation measurements at 0.24 T and 298 K were performed on a Spinmaster FFC, fast field cycling, Stelar, in the following range 0.00024-0.24 T. Three independent experiments were measured for each concentration, and each data point corresponds to one experiment.
Fe (phos) solutions were prepared with 2 mg/ml of Fe 8 in phosphate solutions ranging from 0.01 to 1 M of K 2 HPO 4 salt, at neutral "(7)" and basic "(12)" pH. Relaxivities values are referred to moles of Fe, where 1 mM Fe 8 equals 8 mM Fe.
Spectroscopic and magnetic characterization 31 P spectra of Fe (phos) were performed on a Bruker Avance300 spectrometer operating at a magnetic field of 7.0 T, at 298 K with 5 mm tubes. Spectra of the Fe (phos) were obtained from four samples of a solution 0.5 ml of 10 mg/ml of Fe 8 in 0.005, 0.01, 0.25 and in 1 M aqueous phosphate solutions, respectively, at neutral pH (7 < pH < 7.4). 31 P spectrum of the K 2 HPO 4 salt in aqueous solution was also recorded. 2 H 2 O was used for locking purposes and H 3 PO 4 (85%) as external reference.
Mössbauer spectra of Fe (phos) and the Fe 8 powder, hereafter referred as Fe 8(s) , were recorded at 4.2 K with a conventional transmission spectrometer using a 57 Co source in Rh matrix. Calibration was carried out using a 25-µm thick natural iron foil. Spectra of the Fe (phos) were obtained from two samples of a frozen solution 0.5 ml of 10 mg/ml of 57 Fe 8 in 0.05 M and in 1 M phosphate solutions, respectively, at neutral pH.
The temperature dependences of dc magnetization for the frozen phosphate solution and the Fe 8(s) , samples were measured with a PPMS magnetometer (Quantum Design) over the temperature range 2-250 K in an applied field up to 90 kOe. The experimental results were corrected for the holder contribution as well as for a temperature independent diamagnetic contribution. For the magnetic studies two solutions of 10 mg/ml of Fe 8 in 0.05 and 1 M were prepared at neutral pH. All the magnetization data are presented in emu/mol Fe.
Cells and animals
The C6 cell line from rat glioma was obtained from the European Collection of Cell Cultures (ECACC). Cells were maintained in Ham's F-12 supplemented with 10% foetal bovine serum, 2 mM glutamine and 50 µM gentamicin. C6 glioma cells were grown in culture flasks and passed every 3-4 days. GL261 mouse glioma cells were obtained from the Tumour Bank Repository at the National Cancer Institute, Frederick, USA and constitute a well-established experimental glioma model in mice (17) . These were grown in RPMI-1640 culture medium supplemented with 2.0 g/l sodium bicarbonate, 0.285 g/l L-glutamine, 10% foetal bovine serum (Gibco) and 1% penicillin-streptomycin Solution. Culture medium and chemicals were purchased from Sigma unless otherwise indicated. Culture plastic was obtained from Nunc.
Thirty CD1 mice (Charles-River Labs., France) with weights between 24 and 36 g, were used for toxicity studies. MRI studies were performed with mice harbouring a brain tumour, which is a classic pathology model to demonstrate T 1 contrast effect in vivo (18) . For this we implanted a total of seven mice with murine glioma cells: six with GL261 cells (mice 1-6) (18) and one with C6 cells (mouse 7) (19) . Briefly, animals were anesthetized intraperitoneal (i.p.) with ketamine-xylasine, 80-10 mg/kg, and then immobilized on a stereotactic holder (Kopf Instruments, Tujunga, CA, USA). After the scull was exposed, a 1.0 mm hole was made 2.3 mm lateral (right) to the midline, as measured from the Bregma. A 26G Hamilton syringe (Reno/NV, USA), positioned on a digital push-pull microinjector (Harvard Apparatus, Holliston, MA, USA) was then advanced 2.3 mm from the cortical surface into the striatum, and 4 µl RPMI medium containing 10 5 GL261 (or C6) cells were injected at a rate of 2 µl/min. Three to five minutes after the injection had finished, the syringe was slowly removed, the scission site closed with suture silk (5.0) and the animal left to recover in a warm environment (about 25 • C). Toxicity studies were conducted at the animal facility of the University of Barcelona, where animals were housed. For in vivo tumour studies, animals were housed first at the animal facility of Universitat Autònoma de Barcelona (Servei d'Estabulari), where tumour cells were stereotactically injected, and then transported to the Instituto de Investigaciones Biomedicas "Alberto Sols" UAM-CSIC, Madrid, where MR studies were conducted. Animals were always fed ad libitum, allowed 12-12 h light-dark cycles and were treated according to protocols approved by the animal healthcare committee of each relevant institution.
Toxicity studies

In vitro
For cytotoxicity assays, cells from the C6 glioma cell line were seeded in 12-well plates and treated for 72 h with the Fe (phos) . We used the lactate dehydrogenase (LDH) leakage test that indicates the presence of cell membrane damage (20) . In a previous work we have determined the reliability of LDH test for analyzing Fe 8 cytotoxicity (13) . Using a spectrophotometric NADH consumption assay, in the presence of pyruvic acid substrate, LDH leaked from cells was measured in the culture medium after 72 h exposure to Fe (phos) solutions and expressed as the change in optical density per min ( OD/min).
In vivo
According to spectroscopy and magnetic characterization results obtained previously in vitro (see Results section), Fe (phos) solutions were prepared at a ratio [HPO In vivo toxicity of these Fe (phos) solutions was evaluated in CD1 mice. Different dose levels were administrated by intravenous (i.v.) tail injection with a volume of 4 µl/g. The study was performed with groups of five males and five females per dose. Animals were regularly monitored for two weeks after the injection of Fe (phos) . After that, all surviving animals were sacrificed and autopsied.
MRI studies
Seven mice harbouring a brain tumour were used for MRI studies. These were carried out at 7.0 T on a Bruker PharmaScan 70/16 (SIERMAC, UAM-CSIC), equipped with active shielded gradients, 300 mT/m, and a 30-mm proton RF coil, optimized for the mouse head. Anaesthesia was performed with isoflurane at 1-2.5% in O 2 and the respiratory frequency maintained between 40 and 60 breaths/min. Animals were also thermostatized with a heated water blanket during this procedure. Before immobilization in the MR holder each animal was canulated in the tail vein (i.v.) with a 26G Abbocath-T. For both, animal scanner time economy and to be able to compare the differential effect of the two contrast agents, avoiding at the same time potential interferences of different tumour vascularization on each animal, both Fe (phos) and Gd-DTPA were used in the same experiment with each animal. After detecting each tumour by T 2 weighted imaging, Dynamic contrast enhanced T 1 (DCE-T 1 ) MRI was performed in the slices of interest along with the iv bolus injection of either Gd-DTPA or Fe (phos) solution, both at 4 µl/g. Assuming an approximate 1:11.8 dilution of each contrast agent when spreading into the blood pool of each mice after injection (calculations explained in more detail ahead in the Discussion section), the Fe (phos) dose used in these studies was always kept below those described as non-toxic from both in vivo and in vitro toxicology analysis (1 mM and 0.04 mmol/kg, respectively, see Results section). Order of injection in mice harbouring GL261 tumours was Fe (phos) (0.04 mmol Fe 8 /kg) followed by Gd-DTPA (mice 1-5: 0.2 mmol/kg; mouse 6: 0.04 mmol/kg) after 2 h 30 min-3 h washout period. As for mouse 7, implanted with C6 cells, Gd-DTPA was injected first (0.2 mmol/kg) and, 4 h later, the Fe (phos) solution (0.04 mmol Fe 8 /kg). In all cases, the second contrast agent was not injected until there was a visual washout confirmation of the previous one in T 1 slice group episode); bolus injection of the CA during acquisition of the second image. DCE-T 1 images were then processed with IDL (RSI, France) home written scripts to generate time-course curves that quantified the average contrast enhancement inside the tumours (defined from regions of interest, ROIs). ImageJ freeware software was also used to obtain fusion images (T 2 control images overlapped with colour coded CE-T1 data).
Results
NMR relaxometric studies
The dependence of relaxivities r 1 and r 2 with the concentration of K 2 HPO 4 for a given initial Fe 8 concentration of 1 mM (8 mM of Fe) at 7.0 T is shown in Fig. 1 Fig. 3a and b. In the same manner, Mössbauer spectrum of the powered sample, Fe 8(s) , was recorded for comparison (Fig. 3c) . The differences between the three spectra are evident. For 0.05 M K 2 HPO 4 (Fig. 3a) the spectrum could be fitted using two symmetrical doublets while for 1 M K 2 HPO 4 (Fig. 3b ) the spectrum could be fitted using three subspectra; two symmetric doublets and a magnetically split sextet accounting for about 25% of the total area. On the contrary, the precursor molecule Fe 8(s) (Fig. 3c) Fig. 4a , b, which suggest an antiferromagnetic coupling between Fe ions for both samples. For the powered sample, Fe 8(s) , the χ T(T) curve measured at 90 kOe is also shown in Fig. 4c. χ T values exhibit a plateau at elevated temperatures, then a steadily increase on decreasing temperature up to a certain maximum followed by a rapid decrease indicating that the Fe 3+ clusters have ferrimagnetic spin ordering. Thus, χ T(T) dependence obtained for Fe 8(s) is very different from those obtained for Fe (phos) solutions pointing to a re-arrangement of the Fe 3+ ions in the phosphate solution and the appearance of antiferromagnetic coupling between Fe ions.
Toxicity studies
Hereafter the Fe (phos) doses used for the described studies have been prepared maintaining a ratio [HPO 
In vitro
The effects of Fe (phos) treatment on cell viability in the C6 glioma cell line were studied after exposures of 72 h duration. For this, the standard cell culture medium was replaced by media containing the Fe (phos) solutions. The range of concentrations of Fe 8 studied was 0.1-1 mM and the concentration of phosphate added was 10 mM. Stock solutions pH was adjusted to neutral pH. Figure 5 shows the LDH released by increasing mM concentrations of Fe 8 . No cytotoxicity effects of Fe (phos) were detected in C6 cell cultures in the whole range of concentrations tested.
In vivo
The toxicity assay of Fe 
MRI studies
As shown in Fig. 6 , all DCE-T1 studies performed with Fe (phos) solutions produced a positive contrastenhancement in brain tumours, both for GL261 (mice 1-5, 12 time-course curves: maximum 114±5%- Fig. 6a ; mouse 6, 3 time-course curves: maximum 118 ± 3%- Fig. 6b ) and for C6 (mouse 7, 3 time-course curves: maximum 123 ± 9%- Fig. 6c) , as compared to reference T 1 control images (100%). This is shown with CE-T1 images (III), fusion images (IV) and also with the time-course curves for each contrast agent (V) presented all together in Fig. 6 . Nevertheless, this effect was always inferior to that obtained with Gd-DTPA, either at the standard dose (mice 1-5 and mouse 7, 0.2 mmol/kg: 177 ± 17% and 184 ± 21%, respectively), or at an equivalent dose to that of Fe (phos) (mouse 6, 0.04 mmol/kg: 130 ± 2%). Also, in most GL261 tumour cases studied the contrast enhancement achieved with the Fe (phos) solution was not well distinguished visually after the first minutes post-injection despite being well observed in the time-course curves. The only exception was the single C6 tumour studied, where apparently the washout period of the Fe (phos) solution was much longer.
Moreover, Fig. 7 shows the time-course of the intensity measured in ROIs positioned in the jugular veins (interior and exterior) after bolus injection of each contrast agent. Despite the large standard deviations, it is possible to observe a slightly larger signal enhancement with Gd-DTPA during the initial minutes post-injection (at 1.8 min: 211±121% with Gd-DTPA and 161±42% with Fe (phos) solution) becoming at later times indistinguishable among the two compounds, albeit Gd-DTPA seems to display a tendency to faster clearance from blood than Fe (phos) .
Discussion
In this work, we have characterized the relaxometric properties of the Fe 3+ ions, originated from the rearrangement of the Fe 3+ ions from the initial cation [(tacn) 6 These studies also suggested that the decomposition is catalysed by the phosphate group, and it is followed by formation of a stable, possibly colloidal, suspension of oligomeric species which composition and size is likely to depend on the ratio between Fe and phosphate. It should be pointed out that no precipitation was observed at any pH value or [HPO 2− 4 ]/[Fe 8 ] ratio studied. This is indicative that the amine groups are present in the final product, since otherwise Fe 3+ hydroxides would have precipitated, which was not the case. A possible explanation for the observed increase of relaxivity values at neutral pH as the phosphate concentration is increased could be that the phosphate anion allows the formation of a short-lived second coordination complex where these phosphate ligands promote an approximation of the water protons to the Fe 3+ ions. This dynamic process would be based in the fast exchange of water molecules near physiologic pH with the complex, which would allow this relaxivity increase. Increasing the phosphate concentration would enhance the formation of an oligomeric species which in turn, would result in a decrease of its rotational time. To validate our model, the resolution of the crystal structure of the new compound in the presence of phosphate groups would be of great help. However, in spite of the large number of attempts made using several strategies no acceptable crystals were obtained.
It may be relevant to mention here early work (27) Cytotoxicity studies showed lack of toxic effects for a ratio of [K 2 HPO 4 ]/[Fe 8 ] ≥ 10, suggesting that there are no free iron(III) ions in the phosphate solution in contrast with their presence detected in aqueous solutions in which phosphate was absent (22) . Our preliminary DCE-T1 MRI studies obtained in vivo demonstrate that Fe (phos) solutions produce positive contrast enhancement in glioma brain tumours grown in mice at a dose that presented no toxic effects up to 14 days post-injection in control animals. Nevertheless, Gd-DTPA is clearly more efficient as a contrast agent to highlight blood-brain barrier (BBB) breakdown in brain tumours than the Fe (phos) solution, producing about five times more contrast at the highest doses tested here. Taking into account the fact that both agents produced an identical signal enhancement in the vascular bed, as described in Fig. 7 , the lower enhancement of tumour contrast produced by Fe (phos) could possibly be due to a decrease in the inorganic phosphate (Pi) concentration in the extracellular tumour compartment with respect to the Pi concentration in the mouse plasma. In this respect, Pi concentrations described in the literature for mouse plasma is in the 0.82-3.08 mM range (average 1.95 mM), calculated from (23, 24) . Furthermore, after Fe (phos) i.v. injection (4 µl/g) the plasma Pi levels are expected to rise to about 10.45 mM (assuming 1.1 ml of plasma in a 25 g mouse and an average basal plasma Pi of 1.95 mM). Simultaneously the iron (Fe 8 ) concentration in plasma coming from Fe (phos) injection would be expected to be about 0.85 mM, therefore producing a Pi/Fe (phos) ratio higher than ten. This should produce, as described in the NMR relaxometric studies section, high r 1 values and optimal positive contrast enhancement, as demonstrated from venous blood in Fig. 7 . On the other hand, results shown in Fig. 6 would be coherent with a much lower Pi concentration in the tumour extracellular fluid than in circulating blood causing a decreased effect on water relaxivity and, thus, lower contrast enhancement. Nevertheless, it may be relevant to compare results obtained with GL261 and C6 cells. C6 derived rat glioma tumours are know to be very necrotic (25) . Furthermore, the species difference for cells (C6, rat) and host (mice) in this work would be expected to generate an immune response with concomitant macrophage invasion which could also further increase tumour necrosis. All tumours shown in Fig. 6 had apparent necrotic regions as may be deduced from CE-T1 and fusion images by the typical "ring enhancement" pattern seen (18), using both contrast agents. Furthermore, those tumours appear to contain poorly perfused regions as pointed by the selective slow entry of Gd-DTPA in such areas (as found in time-course curves, results not shown). As expected, the single C6 tumour studied appeared to be more necrotic (slower entry and longer washout time for Gd-DTPA) than GL261 tumours, with some positive contrast already observed in the control T 1 images. In agreement with this, the Fe (phos) solution produced higher and longer lasting contrast enhancement in the C6 tumour than in any of the GL261 tumours studied. This result could be interpreted as due to higher extracellular Pi the more necrotic the tumour is. In this respect, it may be of interest to investigate the performance of Fe (phos) under conditions in which hyperphosphatemia is expected, e.g., in the Tumour Lysis Syndrome (TLS), situation which normally follows chemotherapy treatment of tumours (26) , or for cell tracking applications (28, 29) , due to the fact that intracellular Pi concentration is normally much higher than extracellular Pi.
Conclusions
Fe (phos) solutions present interesting relaxometric properties. For a given initial concentration of Fe 8 , and by varying the concentration of the phosphate salt, the r i value increases to maximal values of r 1 = 2.5 and r 2 = 2.9 mM −1 s −1 for a [HPO ] ≥ 10, the possible colloids that are present in solution are time-stable and its composition and/or size will depend on the concentration of the phosphate salt. In vitro and in vivo toxicity studies of Fe (phos) solutions confirm the lack of detectable toxic effects up to a concentration of 10 mM Fe 8 /100 mM phosphate, suggesting that no toxic free iron ions are eventually released. We have also demonstrated that the Fe (phos) solution is well tolerated by mice at a concentration that enables positive T 1 contrast enhancement of brain tumours albeit less efficient than commercially available compounds, such as Gd-DTPA. The possible application of the Fe (phos) solution for highlighting in vivo hyperphosphatemic regions or its potential use in angiography or cell tracking deserves further investigation.
